Beam has emerged out of Harvard University with $87m in series A funding to commercialise gene editing technology, with additional research licensed from Broad Institute and Editas Medicine.
Beam Therapeutics, a US-based biotech spinout from Harvard University, emerged out of stealth yesterday with a $87m series A round co-led by Arch Venture Partners, the VC firm spun out of University of Chicago.
F-Prime Capital, an investment subsidiary of financial services conglomerate Fidelity, co-led the round.
Beam Therapeutics is working on precision genetic medicines using base editing, a form of genome editing that enables the precise altering of DNA or RNA base pairs using Crispr technology.
The spinout is…
